{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:54Z","timestamp":1790996754651,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.prdoa.2024.100239","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T11:52:04Z","timestamp":1707565924000},"page":"100239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: Considerations for initiation and maintenance"],"prefix":"10.1016","volume":"10","author":[{"given":"Victor S.C.","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha P.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnita J.W.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio F.","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahome","family":"Fisseha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Freire-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Soileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saritha","family":"Talapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Tarakad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Urrea-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Zamudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prdoa.2024.100239_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: Past, Present, and Future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur. Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2024.100239_b0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2024.100239_b0015","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.prdoa.2024.100239_b0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3233\/JPD-212813","article-title":"Foslevodopa\/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion","volume":"11","author":"Rosebraugh","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2024.100239_b0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","article-title":"Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum","volume":"97","author":"Rosebraugh","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100239_b0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ana.26073","article-title":"Foslevodopa\/Foscarbidopa: A New Subcutaneous Treatment for Parkinson\u2019s Disease","volume":"90","author":"Rosebraugh","year":"2021","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2024.100239_b0035","first-page":"1937","article-title":"Continuous Subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study, Neurol","volume":"12","author":"Aldred","year":"2023","journal-title":"Ther"},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0040","first-page":"S23","article-title":"Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa\/Foscarbidopa for Treatment of Advanced Parkinson's Disease","volume":"38","author":"Fung","year":"2023","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100239_b0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0050","first-page":"S51","article-title":"Foslevodopa\/Foscarbidopa in Patients with Advanced Parkinson\u2019s Disease: Subgroup Analyses from a Phase 3, Randomized Study","volume":"38","author":"Soileau","year":"2023","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0055","first-page":"444","article-title":"Subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: Results by Age, Disease Duration, and Baseline \u201cOff\u201d Time","volume":"29","author":"Isaacson","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2024.100239_b0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","article-title":"Does the 5\u20132-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5\u20132-1-positive patients in 7 countries","volume":"22","author":"Malaty","year":"2022","journal-title":"BMC Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2024.100239_b0065","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi panel approach","volume":"34","author":"Antonini","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.prdoa.2024.100239_b0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","article-title":"National Steering Committees, Collective physician perspective on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: Consensus from an international survey and discussion program","volume":"21","author":"Odin","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"7","key":"10.1016\/j.prdoa.2024.100239_b0075","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa Dose Equivalency in Parkinson\u2019s Disease: Updated Systematic Review and Proposals","volume":"38","author":"Jost","year":"2023","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100239_b0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40263-020-00782-w","article-title":"24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations","volume":"35","author":"Thakkar","year":"2021","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.prdoa.2024.100239_b0085","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/mds.27883","article-title":"Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease","volume":"34","author":"Morales-Brice\u00f1o","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2024.100239_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41531-018-0070-4","article-title":"24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson\u2019s disease","volume":"4","author":"Cruse","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2024.100239_b0095","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0145721716642526","article-title":"Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future Directions","volume":"42","author":"Evert","year":"2016","journal-title":"Diabetes Educ."},{"issue":"S2","key":"10.1016\/j.prdoa.2024.100239_b0100","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2018.0080","article-title":"Preserving Skin Integrity with Chronic Device Use in Diabetes","volume":"20","author":"Messer","year":"2018","journal-title":"Diabetes Technol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0105","first-page":"S27","article-title":"Pharmacokinetics, Safety and Tolerability of Foslevodopa\/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank Compared to Abdomen in Parkinson\u2019s Disease Patients","volume":"38","author":"Han","year":"2023","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.prdoa.2024.100239_b0110","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/193229681200600429","article-title":"Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion","volume":"6","author":"Heinemann","year":"2012","journal-title":"J. Diabetes Sci. Technol."},{"issue":"3","key":"10.1016\/j.prdoa.2024.100239_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pcd.2007.07.005","article-title":"International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life","volume":"1","author":"Hammond","year":"2007","journal-title":"Prim. Care Diabetes"},{"issue":"12","key":"10.1016\/j.prdoa.2024.100239_b0120","doi-asserted-by":"crossref","first-page":"576","DOI":"10.12968\/bjnn.2008.4.12.31962","article-title":"Cutaneous side effects of infused apomorphine: The patient and carer experience","volume":"4","author":"Poltawski","year":"2008","journal-title":"Br. J. Neurosci. Nurs."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0125","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.parkreldis.2016.11.017","article-title":"Practical management of adverse events related to apomorphine therapy","volume":"33","author":"Bhidayasiri","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100239_b0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/0145721709352010","article-title":"Practical Aspects of Real-Time Continuous Glucose Monitors: The Experience of the Yale Children\u2019s Diabetes Program","volume":"36","author":"Ives","year":"2010","journal-title":"Diabetes Educ."},{"issue":"9","key":"10.1016\/j.prdoa.2024.100239_b0135","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1080\/03007995.2021.1953971","article-title":"Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions","volume":"37","author":"Jick","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.prdoa.2024.100239_b0140","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/jdv.14345","article-title":"Doxycycline as an anti-inflammatory agent: updates in dermatology","volume":"31","author":"Henehan","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"17, Suppl 2","key":"10.1016\/j.prdoa.2024.100239_b0145","doi-asserted-by":"crossref","first-page":"0004","DOI":"10.1212\/WNL.0000000000201730","article-title":"Safety of Foslevodopa\/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial","volume":"100","author":"Kern","year":"2023","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2024.100239_b0150","first-page":"S32","article-title":"Safety of Foslevodopa\/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3, Single-arm Trial","volume":"38","author":"Kern","year":"2023","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.prdoa.2024.100239_b0155","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100239_b0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1212\/CPJ.0000000000000316","article-title":"Optimizing extended-release carbidopa\/levodopa in Parkinson disease: Consensus on conversion from standard therapy","volume":"7","author":"Espay","year":"2017","journal-title":"Neurol. Clin. Pract."},{"issue":"Sup14c","key":"10.1016\/j.prdoa.2024.100239_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/bjon.2019.28.Sup14c.1","article-title":"A Guide to Subcutaneous Infusion","volume":"28","author":"Gabriel","year":"2019","journal-title":"Br. J. Nurs."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T17:55:55Z","timestamp":1718560555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112524000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":33,"alternative-id":["S2590112524000082"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100239","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: Considerations for initiation and maintenance","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AbbVie Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100239"}}